Multiple myeloma (MM) is a clonal proliferation of malignant plasma cells in the bone
marrow associated with a spectrum of clinical symptoms including bone destruction, anemia …

It is becoming clear that myeloma cell-induced disruption of the highly organized bone
marrow components (both cellular and extracellular) results in destruction of the marrow and …

Proteasome inhibitors (PIs) have been a kind of backbone therapies for newly diagnosed as
well as relapsed or refractory myeloma patients in the last two decades. Bortezomib, the first …

多发性骨髓瘤 (multiple myeloma, MM) 是一种高度异质性恶性浆细胞疾病. 蛋白酶体抑制剂
(proteasome inhibitors, PIs) 是治疗 MM 的一线药物, 硼替佐米, 伊莎佐米和卡非佐米也广泛 …

The majority of intracellular proteins undergo degradation through the ubiquitin-proteasome
pathway. The proteasome pathway has a role in regulating cell proliferation, differentiation …

Background Resistance to proteasome inhibitors bortezomib (BTZ) and carfilzomib (CFZ) is
a major obstacle to the successful treatment of multiple myeloma (MM). Thus, understanding …

With proteasome inhibitors (PIs) becoming clinically available since 2003, outcomes for
patients with multiple myeloma (MM) have dramatically changed, improving quality of life …

Experimental data on resistance mechanisms of multiple myeloma (MM) to ixazomib (IXA), a
second-generation proteasome inhibitor (PI), are currently lacking. We generated MM cell …

Inhibition of proteasome, a proteolytic complex responsible for the degradation of
ubiquitinated proteins, has emerged as a powerful strategy for treatment of multiple …

ABSTRACT Introduction: Proteasome inhibitors (PIs) are therapeutic backbones of multiple
myeloma treatment, with PI-based therapies being standards of care throughout the …